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To the Editor: Tertiary syphilis, including cerebral 
syphilitic gumma, usually occurs >10 years after contract-
ing syphilis (1) and is a rare manifestation since the intro-
duction of penicillin (2). However, progression of syphi-
lis is reported to be faster in HIV-infected patients than 
in those without such infections (3). We report a case of 
cerebral syphilitic gumma in an HIV-1–infected patient for 
whom serum samples obtained as recently as 5 months ear-
lier showed negative results for syphilis.
A 21-year-old man infected with HIV came to the 
AIDS Clinical Center, National Center for Global Health 
and Medicine (Tokyo, Japan), because of a 2-hour loss of 
consciousness. He reported an uncomfortable feeling at the 
back of his head and neck and eye fatigue that lasted for 
1 week. His HIV-1 infection was well-controlled with an 
antiretroviral combination of tenofovir, emtricitabine, and 
dolutegravir. The patient had a CD4 count of 565 cells/mL 
and a viremia level below detectable limits (<20 copies/
mL). He was not using any other medications. 
At examination, his vital signs were within refer-
ence ranges. Apart from a tongue bite, physical and 
neurologic examinations showed no abnormal findings. 
Results for chest radiograph, Holter electrocardiogram, 
and electroencephalogram were unremarkable. There 
were no abnormal ophthalmologic findings. Computed 
tomography of the brain showed a hypodense lesion at 
the left frontal lobe (Figure, panel A). Subsequent mag-
netic resonance imaging showed that the lesion (mass) 
was hypointense by gadolinium-enhanced, axial, T1-
weighted imaging (Figure, panel B), hyperintense by 
T2-weighted imaging, and surrounded by extensive ce-
rebral edema (Figure, panel C).
Symptomatic epilepsy caused by the mass was sus-
pected to have caused the loss of consciousness. This con-
clusion was based on the intracranial mass, long duration of 
loss of consciousness, increase in creatine kinase level (471 
U/L), and tongue bite.
When the HIV-1 infection was diagnosed in the pa-
tient 15 months earlier, results of serum rapid plasma re-
agin (RPR) and Treponema pallidum hemagglutination test 
(TPHA) were negative. However, during this examination, 
serum RPR and TPHA titers were 1:32 and 1:10,240, re-
spectively. Results of cerebrospinal fluid (CSF) analysis 
were compatible with neurosyphilis (4,5) and showed a 
leukocyte count of 35 cells/mL (2 neutrophils/mL, 33 lym-
phocytes/mL), a total protein level of 30 mg/dL, a glucose 
level of 59 mg/dL (serum glucose level 92 mg/dL), an 
RPR titer of 1:<1, a TPHA titer of 1:160, and a fluorescent 
treponemal antibody-absorption titer of 1:32.
Cerebral syphilitic gumma was suspected on the ba-
sis of neurosyphilis and compatible imaging findings (6) 
and because other conditions, such as meningioma, pri-
mary central nervous system lymphoma, toxoplasmosis, 
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cryptococcoma, tuberculoma, or brain abscess, were un-
likely. These results were based on radiologic findings; 
high CD4 cell counts; and negative results for Epstein-Barr 
virus and malignant cells in CSF; serum cryptococcal anti-
gen; CSF culture for bacteria, mycobacteria, and fungi; and 
interferon-γ release assay.
We did not perform a biopsy for the patient because 
of presumed high pretest probability of cerebral syphilit-
ic gumma, the invasiveness of this complication, and the 
young age of the patient. However, successful therapy con-
firmed the diagnosis (3).
We empirically treated the patient with intravenous 
benzylpenicillin (24 million units/d for 14 consecutive 
days). Clinical symptoms improved shortly after treatment. 
At 2-month follow-up, all clinical symptoms and signs had 
resolved, and a 4-fold decrease in RPR titer was observed 
(RPR titer 1:8, TPHA titer 1:5,120) (7). The brain mass was 
substantially reduced, which confirmed the diagnosis of ce-
rebral syphilitic gumma (Figure, panel D).
Gumma is a complication of long-term infection with 
T. pallidum, which develops 1–46 years after healing of 
secondary lesions; most cases develop within 15 years 
(1). However, for our patient, cerebral syphilitic gumma 
developed within 5 months after he contracted syphi-
lis. After written informed consent was obtained, serum 
samples were obtained from the patient at his first and 
subsequent clinic visits and stored. Samples obtained at 
11 months, 10 months, 9 months, 5 months, 11 weeks, 
and 5 weeks before detection of the brain mass were then 
tested retrospectively for RPR and TPHA titers. Results 
were negative at 11, 10, 9, and 5 months before detection 
of the brain mass, but TPHA titers became positive (1:80) 
at 11 weeks before presentation, and RPR titers became 
positive (1:16) at 5 weeks before presentation. Because 
RPR and TPHA titers can become positive as late as 6 
weeks after infection (8), we believe that the patient con-
tracted syphilis within 5 months before documentation of 
the cerebral mass.
In conclusion, we report an HIV-1–infected patient 
in whom cerebral syphilitic gumma developed within 5 
months after contracting syphilis. Cerebral syphilitic gum-
ma should be considered in the differential diagnosis of 
a cerebral lesion in sexually active patients even if they 
had recently contracted syphilis. Moreover, as guidelines 
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Figure. Diagnostic imaging 
results for a brain mass in a 
21-year-old HIV-positive man 
with cerebral syphilitic gumma 
in Tokyo, Japan, for whom 
serum samples obtained as 
recently as 5 months earlier 
showed negative results for 
syphilis. A) Noncontrast, cranial 
computed tomography showing 
a hypodense lesion in the left 
frontal lobe. B) Gadolinium-
enhanced, axial, T1-weighted 
magnetic resonance imaging 
(MRI) showing an enhanced 
lesion (mass) (14 × 14 × 12 mm) 
adjacent to the enhanced dura in 
the left frontal lobe. C) Axial,  
fluid-attenuated inversion 
recovery MRI showing extensive 
left frontal edema. D) Two months 
after treatment for syphilis, 
gadolinium-enhanced, axial T1-
weighted MRI showing substantial 
resolution of the lesion.
recommend (9), screening of HIV-infected patients who 
are sexually active with multiple partners should be con-
ducted every 3–6 months for early detection of syphilis 
and initiation of proper treatment to prevent transmission 
and progression to late syphilis.
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To the Editor: African tick-bite fever (ATBF) is a well 
known disease in travelers to sub-Saharan Africa (1). The 
causative agent, Rickettsia africae, is transmitted to hu-
mans by ticks of the genus Amblyomma (1,2). R. africae 
has been isolated or detected in ticks, humans, or both in 
22 sub-Saharan countries (3). Most ATBF cases have been 
described in tourists returning from countries to which it 
is endemic, most often from South Africa, Zimbabwe, and 
Botswana (4). We report a case of ATBF in a Slovenian 
traveler returning from Uganda.
In June 2015, a 29-year-old Slovenian man without un-
derlying illnesses sought care at the Department of Infectious 
Diseases, University Medical Centre Ljubljana (Ljubljana, 
Slovenia). He had a 1-day history of fever up to 38°C without 
chills, 5 days after returning from a 2-week trip to Uganda. 
He had received vaccines against yellow fever and viral hep-
atitis A before traveling and did not use antimalarial prophy-
laxis during his stay in southwestern Uganda. A day before he 
left Uganda, he noticed a tick bite on his left upper abdomen.
At initial examination, he appeared well. He had a 
temperature of 37.8°C, pulse rate 75 beats/min, and blood 
pressure 120/80 mm Hg. Skin examination was remarkable 
for a solitary papular lesion at the site of tick bite surround-
ed by a small erythematous halo associated with discrete 
lymphangitic streaking and painful enlarged left axillar 
lymph nodes. Results of initially performed routine labora-
tory tests were normal.
On day 5 of illness, the man was still febrile, with a 
temperature up to 39°C. Papular skin lesion had developed 
a dark brown crusted center (compatible with a tache noire), 
and some new discrete asymptomatic pale papular skin le-
sions appeared on his left leg and arm. Repeat laboratory 
testing indicated only mildly increased serum C-reactive 
protein (16.0 mg/L [reference <5 mg/L]).
The clinical course improved rapidly after treatment 
began with doxycycline. Fever resolved in 2 days, and en-
larged lymph nodes and skin lesions resolved completely 
within 14 days.
Microbiological procedures to detect for infection with 
tick-transmitted pathogens were performed to elucidate the 
1848 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016
LETTERS
